JP Morgan Chase
OSTX

JP Morgan Chase’s OS Therapies Inc OSTX Stock Holding History

JP Morgan Chase’s Portfolio OSTX Stock Details OSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-13
Closed -$25 – 7844
2025
Q3 		$25 Sell
13
-309
-96% -$612 ﹤0.01% 7274
2025
Q2 		$605 Buy
+322
New +$542 ﹤0.01% 6681

Other funds holding OSTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

JP Morgan Chase's OSTX Position: Q4 2025 in Review

JP Morgan Chase sold out of OS Therapies Inc (OSTX) in Q4 2025, closing a stake of 13 shares — an estimated $25 sold.

JP Morgan Chase first reported a position in OSTX in Q2 2025 and held it in 2 quarters. The position peaked at $605 in Q2 2025. 25 funds tracked by Wall St. Rank hold OSTX as of Q4 2025.

  • JP Morgan Chase reported no remaining OS Therapies Inc position as of Q4 2025 after selling out during the quarter.
  • JP Morgan Chase sold 13 OS Therapies Inc shares in Q4 2025, an estimated $25.
  • JP Morgan Chase first reported a position in OS Therapies Inc in Q2 2025 and held it in 2 quarters.
  • JP Morgan Chase's OS Therapies Inc position peaked at $605 in Q2 2025.
  • 25 funds tracked by Wall St. Rank held OS Therapies Inc as of Q4 2025.

Based on JP Morgan Chase's 13F filing for Q4 2025, filed 11 Feb 2026.